Velcade

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple MyelomaTrialRemission

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

1

TALVEY

Johnson & Johnson

Phase 3

242

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

423

Biaxin

AbbVie

Phase 3

154

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

295

Treanda

AAzurity Pharmaceuticals

Phase 3

196

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

107

Etentamig

AbbVie

Phase 3

88

Granulocyte Colony-Stimulating Factor

Sanofi

Phase 3

69

Daratumumab SC

Johnson & Johnson

Phase 3

510

G-CSF

AArog Pharmaceuticals, Inc.

Phase 3

11Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Multiple Myeloma28 trials

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Completed·Johnson & Johnson·Phase 3·NCT03217812·220 enrolled

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Completed·Johnson & Johnson·Phase 1·NCT01998971·240 enrolled

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Terminated·NNYU Langone Health·Phase 2·NCT01438177·11 enrolled

Show 25 more trials

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Completed·PPETHEMA Foundation·Phase 2·NCT01237249·250 enrolled

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Completed·PPETHEMA Foundation·Phase 2·NCT01376401·60 enrolled

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Completed·Johnson & Johnson·Phase 3·NCT02195479·706 enrolled

Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00116961·40 enrolled

Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure

Completed·PPETHEMA Foundation·Phase 2·NCT01084837·60 enrolled

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

Terminated·UUniversity of Arkansas·Phase 2·NCT00128921·18 enrolled

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Unknown status·KKorean Multiple Myeloma Working Party·Phase 2·NCT00319865·47 enrolled

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Terminated·Novartis·Phase 2·NCT02720510·6 enrolled

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

Unknown status·PProf Jamie Cavenagh·Phase 1/2·NCT02145715·54 enrolled

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Completed·Johnson & Johnson·Phase 3·NCT03234972·213 enrolled

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT00135187·30 enrolled

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Active, not recruiting·UUniversity of Turin, Italy·Phase 4·NCT03829371·450 enrolled

Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

Completed·Sanofi·Phase 1·NCT01233895·26 enrolled

Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

Completed·PPETHEMA Foundation·Phase 1/2·NCT00388635·60 enrolled

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Completed·Johnson & Johnson·Phase 2·NCT00911859·118 enrolled

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

Completed·Takeda·Phase 1/2·NCT00507442·158 enrolled

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Completed·Johnson & Johnson·Phase 3·NCT02136134·498 enrolled

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

Terminated·UUniversity of Utah·Phase 2·NCT01720043·8 enrolled

IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma

Completed·NNantes University Hospital·Phase 3·NCT00200681·493 enrolled

Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Terminated·NNantes University Hospital·Phase 2·NCT00337506·50 enrolled

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Arkansas·N/A·NCT00569868·11 enrolled

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Active, not recruiting·SStichting European Myeloma Network·Phase 3·NCT03710603·709 enrolled

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Unknown status·MMichele Cavo·Phase 3·NCT01134484·480 enrolled

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

Terminated·—·Phase 2·NCT01729338·17 enrolled

A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA."

Completed·NNantes University Hospital·Phase 3·NCT01971658·358 enrolled

Lymphoma7 trials

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01281917·40 enrolled

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

Completed·GGruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie·Phase 2·NCT00509379·48 enrolled

Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

Completed·SSamsung Medical Center·Phase 1/2·NCT00374699·55 enrolled

Show 4 more trials

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01132911·5 enrolled

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201877·25 enrolled

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00136565·60 enrolled

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Terminated·HHoosier Cancer Research Network·Phase 2·NCT01186458·4 enrolled

Follicular Lymphoma3 trials

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Completed·Takeda·Phase 2·NCT00715208·55 enrolled

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

Completed·Takeda·Phase 2·NCT00636792·73 enrolled

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Terminated·Takeda·Phase 2·NCT00850499·12 enrolled

Myelodysplastic Syndromes1 trial

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00624936·23 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Completed·Takeda·Phase 2·NCT01040871·164 enrolled

27 more indications

Relapsed AML1 trial

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML

Completed·UUniversity of Kentucky·Phase 1·NCT00382954·55 enrolled

Myelodysplastic Syndrome1 trial

Velcade in Myelodysplastic Syndrome - Pilot Study

Terminated·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00440076·28 enrolled

Prostate Cancer1 trial

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Terminated·MMedical University of South Carolina·Phase 2·NCT00103376·23 enrolled

T-Cell Prolymphocytic Leukemia1 trial

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

Withdrawn·SStanford University·Phase 2·NCT01162031

Allogeneic Stem Cell Transplantation1 trial

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Completed·MMassachusetts General Hospital·Phase 1·NCT02312102·22 enrolled

Remission1 trial

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00869232·90 enrolled

Relapsed/Refractory1 trial

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

Completed·SStanford University·Phase 1·NCT01114282·11 enrolled

AIN1 trial

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Unknown status·KKorean Multiple Myeloma Working Party·Phase 2·NCT00378755·62 enrolled

Trial1 trial

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00871013·160 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Completed·Takeda·Phase 2·NCT00343720

Relapsed or Refractory1 trial

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Terminated·—·Phase 2·NCT02535806·2 enrolled

Breast Cancer1 trial

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00237627·107 enrolled

Treatment1 trial

VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates

Completed·KKorean Multiple Myeloma Working Party·Phase 2·NCT00320476·35 enrolled

Nasopharyngeal Carcinoma1 trial

Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

Withdrawn·JJohns Hopkins University·Phase 2·NCT00367718

Minimal Residual Disease1 trial

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled

Kidney Transplant1 trial

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

Completed·UUniversity of Cincinnati·Phase 4·NCT00782821·40 enrolled

Cervical Cancer1 trial

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT00329589·54 enrolled

Transplantation1 trial

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Terminated·EEuropean Society for Blood and Marrow Transplantation·Phase 3·NCT00256776·269 enrolled

Myeloma1 trial

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00469209·60 enrolled

Lupus Nephritis1 trial

Velcade for Proliferative Lupus Nephritis

Withdrawn·TThe Rogosin Institute·Phase 4·NCT01169857

Advanced Cancer1 trial

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00500422·134 enrolled

Leukemia1 trial

VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

Completed·MMassachusetts General Hospital·Phase 1·NCT00505700·36 enrolled

Vaginal Cancer1 trial

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Terminated·WWomen and Infants Hospital of Rhode Island·Phase 2·NCT00106262·38 enrolled

Adenocarcinoma1 trial

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

Terminated·Takeda·Phase 2·NCT00117351

Amyloidosis1 trial

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Completed·Takeda·Phase 1/2·NCT00298766·70 enrolled

Autologous Stem Cell Transplantation1 trial

Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients

Terminated·SShanghai Jiao Tong University School of Medicine·Phase 2/3·NCT00984828·23 enrolled

Unspecified4 trials

VELCADE,Rituximab,Cyclophosphamide and Decadron

Terminated·OOncology Specialists, S.C.·Phase 2·NCT00413959·12 enrolled

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 3·NCT00572169·177 enrolled

UARK 2003-33, Total Therapy III

Completed·UUniversity of Arkansas·Phase 2·NCT00081939·303 enrolled

Show 1 more trial

Study of Temsirolimus, Topotecan, and Bortezomib

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00770731·80 enrolled

Details

Drug Info

Related News